^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Cejemly (sugemalimab)

    i
    Company:
    CStone Pharma, Ewopharma, Pfizer, Pharmalink, SteinCares
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    Apply
    A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma (GEMSTONE-303) (NCT03802591)
    Phase 3
    CStone Pharmaceuticals
    Completed
    Last update posted :
    11/29/2023
    Initiation :
    03/28/2019
    Primary completion :
    07/09/2023
    Completion :
    09/22/2023
    PD-L1
    |
    PD-L1 expression
    |
    capecitabine • oxaliplatin • Cejemly (sugemalimab)
    A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma (GEMSTONE-304) (NCT04187352)
    Phase 3
    CStone Pharmaceuticals
    Completed
    Last update posted :
    11/24/2023
    Initiation :
    12/19/2019
    Primary completion :
    10/07/2022
    Completion :
    10/07/2022
    PD-L1
    |
    PD-L1 expression
    |
    cisplatin • 5-fluorouracil • Cejemly (sugemalimab)
    Safety and Efficacy of NK510 to Treat NSCLC (NCT06097962)
    Phase 1
    Base Therapeutics (Shanghai) Co., Ltd.
    Recruiting
    Last update posted :
    10/25/2023
    Initiation :
    07/01/2023
    Primary completion :
    07/01/2024
    Completion :
    07/01/2024
    PD-L1
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • Tevimbra (tislelizumab-jsgr) • Cejemly (sugemalimab)
    Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy (NCT06031597)
    Phase 3
    Zhejiang Cancer Hospital
    Not yet recruiting
    Last update posted :
    09/12/2023
    Initiation :
    09/15/2023
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    EGFR • ALK • ROS1
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Tyvyt (sintilimab) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • Cejemly (sugemalimab)
    A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer (GEMSTONE302) (NCT03789604)
    Phase 3
    CStone Pharmaceuticals
    Active, not recruiting
    Last update posted :
    08/02/2023
    Initiation :
    12/13/2018
    Primary completion :
    05/15/2023
    Completion :
    06/30/2025
    PD-L1
    |
    PD-L1 expression
    |
    carboplatin • paclitaxel • Cejemly (sugemalimab)
    A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma (NCT04194801)
    Phase 1/2
    CStone Pharmaceuticals
    Completed
    Last update posted :
    02/06/2023
    Initiation :
    12/16/2019
    Primary completion :
    10/20/2021
    Completion :
    10/20/2021
    PD-L1
    |
    Cejemly (sugemalimab) • fisogatinib (BLU-554)
    A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors (NCT04200404)
    Phase 1/2
    CStone Pharmaceuticals
    Completed
    Last update posted :
    05/06/2022
    Initiation :
    12/13/2019
    Primary completion :
    05/13/2021
    Completion :
    08/18/2021
    PD-L1
    |
    PD-L1 expression
    |
    Stivarga (regorafenib) • Cejemly (sugemalimab)